NDAINJECTIONINJECTABLE
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
3/8 — Basic
TRAVASOL 5.5% W/O ELECTROLYTES (amino acids) by Baxter. Approved for muscle atrophy, muscle loss, pressure ulcers. First approved in 1976.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAVASOL 5.5% W/O ELECTROLYTES is an amino acid injection used for parenteral nutrition in patients with muscle atrophy, muscle loss, and pressure ulcers. It provides essential amino acids intravenously to support protein synthesis and tissue repair. This product is a foundational nutritional therapeutic with no active mechanism of action classification.
LOE Approaching
Late-stage product with LOE approaching and moderate competitive pressure (30/100), signaling declining team investment and potential headcount reductions in coming years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on TRAVASOL 5.5% W/O ELECTROLYTES at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.